Abcam, ab253556, Human FGL1 Antibody Pair - BSA and Azide free

Size: 10 x 96Tests
Human FGL1 Antibody Pair - BSA and Azide free is a kit containing recombinant capture and detector antibodies in a carrier-free formulation for the measurement of Human FGL1.
Key facts
Reacts with:Human,
Assay type:ELISA set,
Range:78.125 - 5000 pg/mL,
Assay Platform:Reagents

Product details:
Human FGL1 Antibody Pair is a matched pair of unconjugated
recombinant rabbit monoclonal
capture and detection antibodies used to quantify Human FGL1 in sandwich ELISAs and many other pair-based applications.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
The pair can be used in variety of assays and platforms including but not limited to:
Sandwich ELISA
FRET/TR-FRET/HTRF
Meso Scale Discovery
Bead-based assays
AlphaLISA
/AlphaScreen
DELFIA
immunoassays
and Single Molecule Counting (SMC™) immunoassays
Multiplex
Our antibody pairs are supplied in a carrier-free format that is conjugation-ready:
Buffer free of BSA, sodium azide, and glycerol for higher conjugation efficiency.
Concentration of ~1 mg/ml as measured by the protein A280 method.
We can label antibodies for you: get in touch today to discuss how we can help accelerate your assay development with custom conjugation services.
Pairs are screened in biological samples, including plasma and serum, to ensure specificity in complex samples.
Please note:
The recommended antibody orientation is based on internal optimization in sandwich ELISA. Antibody orientation is assay dependent and needs to be optimized for each assay type.
The range provided for this antibody pair is based on initial sandwich ELISA validation data using recombinant protein. Performance and range of the antibody pair will depend on the specific characteristics of your assay, including standard protein selection.
We guarantee the product works in sandwich ELISA, but we do not guarantee the sensitivity or dynamic range of the antibodies in other assays.
Antibody properties:
Capture antibody:
recombinant rabbit monoclonal (unconjugated) – 100 µg
Detector antibody:
recombinant rabbit monoclonal (unconjugated) - 100 µg
Concentration
: ~1 mg/ml
Storage buffer:
100% PBS
Liquid
Isotype:
Recombinant monoclonal antibodies offer several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free production
Meso Scale Discovery and MSD are registered trademarks of Meso Scale Diagnostics, LLC.
AlphaLISA, AlphaScreen, and DELFIA are registered trademarks of PerkinElmer, Inc.
Simoa is a registered trademark of Quanterix, Inc.
SMC is a registered trademark of Merck KGaA, Darmstadt, Germany.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Fibrinogen-like protein 1 (FGL1) also known as Hepassocin plays a significant role in modulating immune responses. FGL1 is a member of the fibrinogen family with a molecular mass of approximately 31 kDa. This protein is widely expressed in the liver and is also found in other tissues like the pancreas and lungs. Its structural homology to fibrinogen suggests potential binding capabilities with similar ligands influencing its mechanical actions in cellular processes.
Biological function summary
FGL1 modulates the immune system and maintains its homeostasis. It functions primarily as a ligand for the immune checkpoint receptor LAG-3. This FGL1-LAG-3 interaction inhibits T-cell activity leading to immune tolerance and helping prevent autoimmunity. FGL1 while not a part of a complex demonstrates significant standalone biological activity by affecting immune responses especially under pathological conditions.
Pathways
FGL1 integrates into the immune regulatory framework. It exerts its effects mainly through the immune checkpoint pathway impacting T-cell regulation. In addition to LAG-3 FGL1 interacts closely with the PD-1/PD-L1 pathway which is also important in checkpoint inhibition and immune evasion mechanisms. These pathways together orchestrate the immune surveillance system and play roles in maintaining immune equilibrium.
FGL1 has received attention in cancer particularly in its role of suppressing anti-tumor immunity. Its interaction with LAG-3 makes it a potential target for cancer immunotherapy as high FGL1 levels correlate with poor prognosis in various cancers. Additionally it has implications in autoimmune diseases where its regulation of T-cell activity prevents excessive immune responses. By modulating LAG-3 activity FGL1 emerges as a therapeutic target of interest in autoimmune conditions presenting new opportunities for managing such disorders.